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Objective:To compare the clinical characteristics and outcomes of patients with acute heart failure (AHF) 
according to clinical profiles based on congestion and perfusion determined in the emergency department 
(ED) 
Methods: 11,261 unselected AHF patients from 41 Spanish EDs were classified according to perfusion 
(normoperfusion=warm; hypoperfusion=cold) and congestion (not=dry; yes=wet). Baseline and 
decompensation characteristics were recorded as were the main wards to which patients were admitted. The 
primary outcome was 1-year all-cause mortality; secondary outcomes were need for hospitalisation during 
the index AHF event, in-hospital all-cause mortality, prolonged hospitalisation, 7-day post-discharge ED 
revisitfor AHF and 30-day post-discharge rehospitalisation for AHF. 
Results: 8,558 patients (76.0%) were warm+wet, 1,929 (17.1%) cold+wet, 675 (6.0%) warm+dry,and 99 (0.9%) 
cold+dry; hypoperfused(cold) patients were more frequently admitted to intensive care units and geriatrics 
departments, and warm+wet were discharged home without admission.The four phenotypes differed in most 
of the baseline and decompensation characteristics. The 1-year mortality was 30.8%, and compared to 
warm+dry, the adjusted HRs were significantly increased for cold+wet (1.660; 95%CI=1.400-1.968) and 
cold+dry (1.672; 1.189-2.351). Hypoperfused (cold) phenotypes also showed higher rates of index episode 
hospitalisation and in-hospital mortality, while congestive (wet) phenotypes had a higher risk of prolonged 
hospitalisation but decreased risk of rehospitalisation. No differences were observed among phenotypes in 
ED revisit risk.   
Conclusions: Bedside clinical evaluation of congestion and perfusion of AHF patients upon ED arrival and 
classification according to phenotypic profiles proposed by the latest ESC Guidelines provide useful 
complementary information and help to rapidly predict patient outcomes shortly after ED patient arrival. 
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Acute heart failure (AHF) is considered a syndrome in which new therapeutic approaches have systematically 
failed to improve survival1-3. One of the most relevant causes proposed to explain this failure is the inclusion 
of patients with different phenotypes in clinical trials. This lack of patient homogeneity has been partially due 
to the absence of an adequate form of classification of clinical phenotypes of AHF. While it is well accepted to 
base the classification of patients with chronic heart failure (CHF) on the left ventricular ejection fraction 
(LVEF), the classification of the episodes of decompensation has evolved. The most recent European Society 
of Cardiology (ESC) Guidelines have now changed from the previous clinical classification based on six 
phenotypical forms (worsening or decompensated CHF, pulmonary oedema, hypertensive heart failure, 
cardiogenic shock,  isolated right heart failure, and acute coronary syndrome and heart failure)4 to one based 
on the intensity of congestion and perfusion5.This latter clinical classification is based on physical bedside 
evaluation of clinical symptoms/signs of congestion (‘wet’ vs. ‘dry’ if present vs. absent) and peripheral 
perfusion (‘cold’ vs. ‘warm’ if hypoperfused vs. normoperfused). The combination of these two conditions 
identifies four phenotypical groups: warm-wet (well perfused and congested), cold-wet (hypoperfused and 
congested); cold-dry (hypoperfused without congestion); and warm-dry (compensated, well perfused without 
congestion). However, while the prognostic potential of this clinical classification has been well-
demonstrated, its possible impact on more personalized medicine remains unclear, and indeed, is an 
ongoing area of investigation. 
Since the publication of the 2016 ESC Guidelines, the only study assessing the potential role of classification in 
clinical phenotypes in AHF prognostication is the analysis of the ESC-HF-LT Registry reported by Chioncel et 
al.6. Nonetheless, the ESC-HF-LT registry only enrolled AHF patients admitted to 211 cardiology centres, and 
therefore, generalisation of these findings to the whole universe of AHF patients (including those admitted to 
other hospital departments or completely managed in the ED without hospitalisation) remains to be 
elucidated. In particular, the potential applicability of this classification in the ED setting has not previously 
been assessed. If prompt classification based on the first ED findings of congestion and perfusion were 
potentially able to identify different patients with different outcomes, it could be of value to promote its 
use in this particular setting. Taking these considerations into account, we evaluated the clinical 
characteristics and the therapeutic approach of the acute episode of decompensation as well as outcomes in 
the four different clinical phenotypes defined by the 2016 ESC Guidelines in order to provide evidence about 
the potential value of this classification in the real world. 
  












The present study was a secondary analysis within the EAHFE Registry. The EAHFE Registry was initiated in 
2007 and every 2-3 years it carries out a 1-2-month recruitment period of all consecutive patients diagnosed 
with AHF in Spanish EDs participating in the project. To date, 6 recruitment phases (in 2007, 2009, 2011, 
2014, 2016 and 2018) have been performed with the participation of 45 EDs from community and university 
hospitals across Spain (representing about 15% of the Spanish public health care system hospitals), enrolling 
a total of 18,370 AHF patients. The present study included data from the 11,360 patients recruited in phases 
3 to 5, since data needed to classify AHF patients according to the phenotype defined in the 2016 ESC 
Guidelines5 were not recorded in phases 1 and 2, and follow-up data of EAHFE-6 patients were not yet 
available when this study was designed. Details of patient inclusion have been reported previously7,8. The AHF 
diagnosis was based on the Framingham clinical criteria9. Attending emergency physicians performed the 
initial patient inclusion and data recording, and all data were obtained within the first 6 hours of ED patient 
arrival. In some cases, especially patients arriving to the ED at night, data were recorded the next morning, 
but these data always referred to the time of patient presentation at the ED. Thereafter, the principal 
investigators of every centre retrospectively reviewed medical reports and made the final diagnostic 
adjudication at a local level. They revised every case to check the compliance of AHF criteria and to confirm 
diagnosis by measurement of plasma natriuretic peptides and/or echocardiography during ED or hospital 
stay, when possible, following the current ESC Guidelines recommendations 5 (available in about 92% of 
cases). The EAHFE Registry does not include any planned intervention, and the management of patients is 
entirely based on the attending ED physician decisions.  
Ethics 
The EAHFE Registry protocol was approved by a central Ethics Committee at the Hospital Universitario Central 
de Asturias (Oviedo, Spain) with the reference numbers 49/2010, 69/2011, 166/13, 160/15 and 205/17. Due 
to the non-interventional design of the registry, Spanish legislation allows central Ethical Committee 
approval, accompanied by notification to the local Ethical Committees. All participating patients gave 
informed consent to be included in the registry and to be contacted for follow up. The present study was 
carried out in strict compliance with the Declaration of Helsinki principles. 
Design and variables recorded 
The attending physician assessed the presence of clinical signs and symptoms of perfusion and congestion 
following the 2016 ESC Guidelines6 during the first patient assessment in the ED. Congestion was accepted 
by the clinical presence of pulmonary congestion, orthopnoea/paroxysmal nocturnal dyspnoea, peripheral 
bilateral oedema, jugular venous dilatation, congested hepatomegaly, gut congestion, ascites 
and/orhepatojugular reflux. Hypoperfusion was considered to be present with cold sweaty extremities, 
oliguria, mental confusion, dizziness and/or narrow pulse pressure (that was clinically ascertained and 










accepted based on physician perception of weak pulse) were identified. Thereafter, patients were classified 
into one of the four phenotypic groups defined by the ESC Guidelines: 1) warm (no signs or symptoms of 
hyppoperfusion) and dry (no signs or symptoms of congestion), which was considered as the reference group 
for comparisons; 2) warm (no hypoperfusion) and wet (presence of any sign or symptom of congestion); cold 
(presence of any sign or symptom of hypoperfusion) and wet (congestion); and 4) cold (hypoperfusion) and 
dry (no congestion).  
Twenty-two independent variables related to demographics (2 variables), comorbidities (13 variables), 
baseline status (3 variables) and chronic treatments for heart failure (5 variables) that could potentially affect 
clinical outcomes were recorded to adjust outcomes for potential differences among groups. In addition, 17 
variables about the current AHF episode were recorded to delineate characteristics of decompensations of 
the four clinical phenotypes. These consisted of vitals at ED arrival (3 variables), analytical data at ED (7 
variables), and data related to ED management during the acute episode (7 variables) (see Supplemental 
Table 1 for definitions). The disposition of the patients after ED care (admission/discharge) was recorded, and 
when hospitalised, the department to which the patient was admitted was recorded, with special focus on 
the main departments where AHF patients are usually admitted in Spain: cardiology, internal medicine, 
geriatrics, short-stay unit and intensive/coronary care unit. 
Outcomes 
The primary outcome in the present study was 1-year all-cause mortality. Five additional secondary outcomes 
were measured and consisted in:1) need for hospitalisation during the index event;2) in-hospital all-cause 
mortality during the index event;3) prolonged length of hospitalisation (LOH) during the index event, defined 
as a hospital stay longer than 7 days counted from the ED visit; 4) ED revisit due to AHF within the 7 days 
after patients discharge; and 5) hospitalisation due to AHF within 30 days after discharge (this outcome was 
only recorded in the EAHFE 4 and 5 phases, but not in EAHFE 3). Follow-up was performed by consultation 
of medical records electronically accessible in nearly all Spanish communities. In addition, patients were 
contacted when no clear data was present in the clinical history or access to data was not possible, as at 
the time of patient inclusion into the EAHFE Registry they provide phone numbers and permission to be 
called.Death was also determined through the Spanish database of public health insurance, that covers 
>99% of Spanish population. Upon death patients are immediately withdrawn from the database. 
Statistical analysis  
Continuous variables are expressed as mean and standard deviation (SD) or median and interquartile range 
(IQR) if not normally distributed, and categorical variables as absolute values and percentages. Comparison 
among the four phenotypical groups was carried out using one-way ANOVA for continuous variables (or by 
Kruskal Wallis non-parametrical test if not normally distributed) and the chi square test for categorical 
variables. Curves depicting proportional hazard for 1-year survival for the four clinical phenotypes were 
plotted using the Cox regression method. Outcomes of patients according to clinical phenotype were 










compared to the warm-dry clinical phenotype by means of Cox regression (for the primary outcome) and 
logistic regression (for secondary outcomes), and the results were expressed as hazard ratios (HRs) and odds 
ratios (ORs) with 95% confidence intervals (95% CI), respectively. The HRs and ORs were then adjusted for 
differences in demographics, comorbidities, baseline status and chronic treatment which were statistically 
significant (p<0.05) in the univariate analysis. Missing values in the variables included in the adjusted models 
were replaced using the multiple imputation technique, generating 5 datasets in which there were no missing 
values among all the variables included in the adjustment. The signs and symptoms presented during the 
acute episode of decompensation were not included in the adjusted model, as differences in clinical 
phenotypes essentially refer to characteristic findings during decompensation. The same concept was used 
for data regarding patient management in the ED, because it is driven by the clinical phenotypes. Therefore, 
for all these data regarding acute decompensation, differences among phenotypes were assessed from an 
unadjusted purely descriptive perspective. We made a subanalysis of primary and secondary outcomes 
stratified by the type of AHF episode (de novo vs. acutely-decompensated), the LVEF (below vs. above 50%) 
and the final destination after ED care (discharge vs. hospitalisation).Statistical significance was accepted if 
the 95%CI excluded the value 1, or the p value was less than 0.05. Since this was an exploratory study, a pre-
hoc sample size calculation was not made. 
  











Patient distribution among phenotype categories 
Of the 11,360 patients included in the EAHFE registries 3 to 5, 62 were excluded due to lack of data for 
phenotype classification and 37 due to lack of follow-up data regarding 1-year mortality (primary 
outcome); therefore, 11,261 (99.1%) provided the key data included in the present analysis 
(Supplementary Figure 1). There were 8,558 patients (76.0%) classified as warm-wet (no hypoperfusion, 
congestion), 1,929 (17.1%) as cold-wet (hypoperfusion, congestion), 675 (6.0%) as warm-dry (no 
hypoperfusion, no congestion), and 99 (0.9%) as cold-dry (hypoperfusion, no congestion). This distribution of 
clinical phenotypes differed according to the main patient destinations after ED care. The intensive care unit 
and geriatrics department had the highest percentage of patients with hypoperfusion, and cardiology 
departments and patients discharged home without hospitalisation had the lowest percentages of 
hypoperfusion phenotypes (Figure 1). Patients discharged home without hospitalisation had the highest 
proportion of warm-wet phenotype (81.7%) among all final destinations after ED care. On the other hand, 
there were differences in phenotype distribution between patients with de novo and acutely-
decompensated heart failure (p<0.001) and between patients with a LVEF below and above 50% (p<0.001). 
The warm-wet phenotype was more frequent in patients with acutely-decompensated heart failure and 
LVEF ≥50%, while cold-wet was more frequent in patients with de novo AHF and with LVEF <50% (Figure 1). 
Main patient baseline characteristics 
Overall, the mean age of the patients was 80 years (SD:10), and 55.5% were women. The patients had a high 
number of comorbidities, the most frequent being hypertension, previous episodes of AHF, atrial fibrillation 
and diabetes mellitus (Table 1); 63.9% also presented some degree of limitation in functional class (i.e., 
Barthel index < 100) and 34.3% had  some degree of systolic dysfunction (LVEF <50%). With respect to chronic 
treatments, 58.8% was receiving renin-angiotensin system (RAS) inhibitors, 42.7% betablockers, and 16.8% 
mineral corticosterid-receptor antagonists (MRA). The four clinical phenotypes differed in many of these 
variables (Table 1).   
Acute heart failure management according to phenotype 
With respect to the current episode, 17 variables were compared across phenotypes (Table 1), and all but 
one significantly differed among the 4 AHF phenotypes. The use of intravenous morphine was higher in the 
cold-wet and cold-dry groups (14.3% and 13.3%, respectively) compared to the warm-dry and warm-wet 
groups (5.4% and 4.3%, respectively) (p<0.001). Inotropic drugs and vasopressors were also more frequently 
used in the former groups (4.9% and 6.1%) compared to the latter groups (0.9% and1.1%) (p<0.001). The 
cold-wet group presented lower oxygen saturation value, higher NT-proBNP values and greater need for the 
use of non-invasive mechanical ventilation (16.4%) compared to the other groups (p<0.001).The use of 
mechanical ventilation was higher in the cold-dry (5.1%) and cold-wet groups (4.9%) compared to the other 
groups (p<0.001)(Table 1). 










Primary and secondary outcomes across clinical phenotypes 
Since the 37 patients without data for mortality (primary endpoint) were excluded from the final analysis 
(0.3% of the whole cohort; Supplementary Figure 1), all patients accounted for the analysis of 1-year 
mortality, which was 30.8% for the whole cohort (warm-dry 23.9%, warm-wet 27.1%, cold-wet 42.0%, cold-
dry 42.4%).  Compared to the warm-dry phenotype, the cold-wet and cold-dry phenotypes had a significantly 
incremented risk of death, while the warm-wet phenotype had a risk very similar to the warm-dry phenotype 
(Figure 3). Similar patterns were observed in the analysis stratified by de novo/acutely-decompensated 
heart failure, by LVEF below/above 50% and by hospitalised/discharged patients (Figure 2). On analysing 
each individual phenotype, we observed that warm-dry, warm-wet, and cold-wet patients with acutely-
decompensated heart failure had worse prognoses than their comparators with de novo AHF;cold-wet 
patients with LVEF <50% had a worse prognosis than those with LEVF >50%; and hospitalised warm-dry and 
warm-wet patients had a worse prognosis than those discharged . 
Regarding secondary outcomes, data was lacking for need of hospitalisation, in-hospital mortality, 
prolonged hospitalisation, post-discharge ED revisit and post-discharge hospitalisation in 0.1%, 0%, 2.0%, 
1.9% and 30.5% of patients, respectively (the latter because post-discharge hospitalisation was not 
recorded during the EAHFE-3 phase). Overall, 75.8% of patients required hospitalisation during the index AHF 
episode, 7.7% died before discharge, 36.0% had prolonged hospitalisation, 11.2% of discharged patients 
revisited the ED during the 7 following days after discharge, and 14.6% were hospitalised within 30 days after 
discharge. With the exception of the 7-day ED revisit, there were significant differences in outcomes among 
the four clinical phenotypes (Figure 3).  
The unadjusted and adjusted risks for primary and secondary outcomes for the rest of the phenotypes, 
compared to the warm-cold phenotype, are shown in Figure 4, and these unadjusted and adjusted risks 
remained consistent in both, direction and magnitude of associations for every outcome. Regarding mortality, 
groups with hypoperfusion showed a clear increased risk (66% and 67% of increments depending on the 
presence or absence of congestion, respectively). Hypoperfusion was also associated with the need for 
hospitalisation at the index AHF episode and death during this index hospitalisation. Phenotypes including 
congestion were associated with a higher risk of prolonged hospitalisation (27% and 52% increase depending 
on the absence or presence of hypoperfusion, respectively), and a decreased risk of hospitalisation due to 
AHF during the 30 days following discharge (31% and 27% of reduction, respectively). Finally, no statistically 
significant differences were observed among phenotypes in the risk of ED revisit due to AHF during the 7 days 
following patient discharge. The stratified analysis showed very similar estimations for all subgroups of 
patients (Table 2). 
  











The present study is the first to describe the characteristics of a wide sample of patients with AHF at ED 
arrival according to the phenotype classification proposed by the 2016 ESC Guidelines on AHF, which is 
based on clinical evaluation of congestion and perfusion. Of note, this approach contains a higher 
representation of patients with HFpEF (close to two thirds in our study) in comparison with other series of 
patients hospitalised in cardiology departments. Remarkably, this new phenotypic classification based on 
clinical evaluation of congestion and perfusion is very helpful in the initial evaluation of patients with AHF 
which usually takes place in the ED and can be performed at bedside without the need for time consuming 
invasive measures or techniques requiring previous training, providing useful prognostic information for the 
initial clinical decision making.  
The first main finding of the current study is that the predominant phenotypic group in the ED is warm-wet 
(in which 3 out of 4 patients with AHF are classified) while the least frequent group is cold-dry (with 1% of the 
cases), and this distribution is very similar to that reported by Chioncel et al.6. However, our results extend 
this phenotype distribution to the whole spectrum of patients with AHF and not only to those admitted to 
cardiology wards. Notably, slight, albeit statistically significant, differences were found in the distribution of 
patients according to the final destination after ED management. Thus, patients discharged directly from the 
ED without admission are mainly warm-wet (82%), while the percentage of hypoperfused patients (cold; with 
or without congestion) increases in internal medicine (21%), geriatric (26%) and especially in intensive care 
wards (39%). In the latter department, the largest percentage of these patients is likely related to the 
haemodynamic profiles of these patients at ED arrival, since this group usually presents more episodes of 
cardiogenic shock. However, it should be highlighted that not all patients with hypoperfusion are in 
cardiogenic shock. In this regard, Chioncel et al.’s paper showed that hypoperfusion was present in more than 
10% of cases included in the hypertensive category. This fact probably explains the high presence of 
hypoperfusion in internal medicine and geriatric wards and represents very advanced forms of chronic heart 
failure in elderly patients, most of whom could receive palliative care10. Remarkably, in both our series and 
that of Chioncel et al., a few AHF patients were warm-dry (15% and 6%, respectively) and probably 
represent the mildest forms of AHF, with very subtle clinical signs of congestion or hypoperfusion. These 
patients are diagnosed with AHF based by echocardiography or natriuretic peptides rather than clinical 
findings, and could be treated in specialised units or at walk-in centres. Nonetheless, in universal public 
health systems such as those in Europe, most of these patients spontaneously come to the ED and are even 
hospitalised. 
The use of intravenous diuretics in the ED was very frequent, in 85% of the cases, in agreement with the 93% 
of patients who presented congestion, and the use of these drugs was also more frequent in the warm-wet 
and cold-wet groups than in the other two categories. Likewise, oxygen was more frequently administered to 
the congestive categories (wet), possibly reflecting a higher difficulty of oxygen diffusion in congestive lungs. 
The use of morphine and non-invasive mechanical ventilation was more frequent in the hypoperfusion 
phenotypes (cold), possibly indicating the greater severity of these patients. Although vasopressors are not 










frequently used in the ED (2%), their use was concentrated, as expected, in hypoperfused patients. On the 
other hand, vasodilatators were more frequently used in cold+wet congestive patients, likely because their 
use in hypoperfused but hypovolemic patients carries an elevated risk of hypotension which, in turn, is 
associated with a high risk of increasing hypoperfusion. Although current guidelines support the generalised 
use of vasodilators in congestive patients who are not hypoperfused5, it should be highlighted that this did 
not occur in our series. Unfortunately, we were unable to find studies comparing the characteristics of 
patient management in the ED based on the phenotypic profile of the patients, and therefore, we cannot 
generalise our results.  
It is clear that the different phenotypic categories carry different outcomes. The presence of hypoperfusion 
(cold) is related to a greater in-hospital and one-year mortality, and these increases do not depend on the 
different basal profile or patient comorbidities, as our results remained consistent after adjustment for these 
differences. This worse prognosis for patients with hypoperfusion was observed in the analysis of the 
whole cohort, as well as in the separated analysis for patients with de novo or acutely-decompensated 
heart failure, LVEF below or above 50% and for patients admitted or discharged after ED care. While the 
subanalysis based on LVEF showed similar curves for both patient categories based on LEVF in every 
phenotypic group (except for cold-wet group), admitted patients had a worse prognosis than those 
discharged from ED to home, probably indicating that emergency physicians admitted the sickest patients 
of each phenotypic category, and differences were statistically significant for the warm-dry and warm-wet 
phenotypes. Similarly, patients with acutely-decompensated heart failure had worse prognoses in each 
phenotype (except for the cold-dry) than patients with de novo AHF. In our study, the in-hospital mortality 
for the cold-wet group was 15% and the mortality at one year increased 66% compared to the control group 
(warm-dry). This increase in mortality is due, in part, to the fact that these patients presented a lower mean 
blood pressure than the other 3 groups. This inverse relation between blood pressure value and mortality has 
been largely demonstrated and, indeed, is included in most risk stratification scales in patients with AHF6,7,11-
13. In addition, in our study hypoperfused patients more frequently required admission, possibly 
demonstrating that management of congestion is easier than hypoperfusion for emergency medicine 
physicians.  
In contrast, it seems that congestion (wet) affects the outcomes of patients with AHF differently from 
hypoperfusion, as it does not impact mortality. This was observed despite the majority of patients, 
irrespective of the phenotype, receiving drugs directed to reduce congestion (diuretics and vasodilators). 
Currently, it is widely accepted that while clearly improving symptoms in patients with AHF, these drugs 
have no impact on patient survival14-16. Remarkably, in the current study, the presence of congestion 
conditioned onger hospital stay, with increases of 27% and 52% of prolonged admissions depending on the 
concomitant absence or presence of hypoperfusion, respectively, compared to the warm-dry group. In 
previous studies which analysed the length of hospitalisation in patients with AHF, it was observed that 
patients with a larger number of comorbidities had longer hospitalisation periods17-20, and similarly, in our 
study comorbidities were generally more prevalent in patients with congestion. However, it is of note that 










despite adjustment for differences in comorbidity, the increase in prolonged admissions was maintained and 
thus, future studies are needed to determine the real causes of this increase. On the other hand, we also 
observed that patients with congestion had a lower risk of rehospitalisation for AHF after discharge following 
the index episode (reduction of 31% and 27% in risk compared to the dry-warm group based on the absence 
or presence of hypoperfusion, respectively). However, the study of Chioncel et al.6 showed that around one 
out of every five patients with AHF admitted to cardiology units still present peripheral and pulmonary 
congestion at hospital discharge. As our AHF patients with congestion had longer hospital stay, perhaps the 
possibility of effectively continuing in-hospital treatment of congestion with diuretics would favour this better 
outcome of patients in this particular aspect. Finally, it is of note that no clinical phenotype was related to an 
increased or decreased risk of reconsultation to the ED for AHF during the week following discharge. This 
should be placed into the context of the public healthcare system such as that in Spain, in which many factors 
not directly related to the morbid process determine the use of EDs. 
Our study has some limitations. First, this was an observational study and causal relationships between 
phenotypes and outcomes cannot be inferred. The retrospective assessment of the classification into the four 
phenotypes might introduce some degree of bias. Moreover, although signs and symptoms were 
prospectively recorded by attending physicians, classification into clinical phenotypes was retrospectively 
performed at the time of data exploration for the present study. Indeed, no ED clinical manoeuvre or 
treatment was influenced by the clinical phenotype beyond the potential use of attending physicians in 
their usual practice. Therefore, our findings are not a result of the impact of using the clinical phenotype 
classification during ED care by emergency physicians, but rather merely describe how these different 
phenotypes are currently being managed in the ED and demonstrate the feasibility of phenotype 
classification in the ED setting. Second, since this study is observational and the number of patients 
analysed was large, it is possible that some findings may be statistically significant but not clinically 
relevant. Third, in this real life cohort without intervention, attending physicians followed their usual local 
protocols and did not receive any specific instructions about the precise time for ED or hospital discharge and 
patient transition. Although this imposes limitations in some of our conclusions, it otherwise makes our 
findings more generalizable. Fourth, the use of clinical criteria could determine, to some extent, patient 
distribution across phenotype categories, as most of the Framingham major criteria and some of the minor 
criteria are signs and symptoms of congestion. Additionally, in patients without signs of congestion or 
hypoperfusion (warm-dry, 6%), AHF diagnosis was mainly made by the presence of dyspnoea (referred by 
the patient), elevated natriutetic peptides and exclusion of other alternative diagnoses, leaving the 
possibility that a few of these patients could have had a diagnosis other than AHF. On the other hand, 
subtle data of congestion or hypoperfusion could have remained unidentified during ED evaluation in 
patients erroneously classified as warm-dry phenotype. Fifth, the patients were from a single country with a 
universal public healthcare system, and since international heterogeneity in organizational and transition 
processes is high21, our results should be confirmed in other countries with different healthcare system 
models. In particular, we report 24% of direct discharge home after ED care, which is higher than that 
observed in other countries, such as the United States22. And sixth, the diagnosis of AHF was based on 










clinical criteria, and the final diagnosis of AHF was not supported in all cases by natriuretic peptide or 
echocardiographic results. 
In view of the results of the present study, clinical evaluation of congestion and perfusion at the bedside of 
patients with AHF at arrival at the ED and the classification of patients into the four phenotypic profiles 
proposed by the last ESC Guidelines provide complementary information about patient management in the 
ED. Moreover, destination after ED healthcare differs according to clinical phenotypes. Finally, the 
classification into the four categories based on perfusion and congestion signs and symptoms is associated 
with outcomes. The clinical implications of all these findings are that the phenotypic classification of the 
2016 ESC Guidelines could be used at a very early stage when patients are diagnosed with AHF in the ED, 
and could help to better estimate patient prognosis and, eventually, provide more individually-guided 
therapy. 
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BASELINE CHARACTERISTICS        
Demographic data        
Age (years) (mean (SD)) 80 (10) 79 (12) 80 (10) 82 (10) 82 (10) <0.001 8 (0.1) 
Female 6,229 (55.5) 353 (52.6) 4,676 (54.9) 1,146 (59.6) 54 (54.5) 0.001 45 (0.4) 
Comorbidities        
Hypertension 9,447 (84.0) 528 (78.2) 7,205 (83.4) 1,635 (84.8) 79 (79.8) <0.001 13 (0.1) 
Diabetes mellitus 4,721 (42.0) 252 (37.3) 3,579 (41.9) 845 (43.9) 45 (45.5) 0.026 14 (0.1) 
Ischaemic heart disease 3,243 (28.8) 178 (26,4) 2,428 (28.4) 601 (31.2) 36 (36.4) 0.014 13 (0.1) 
Chronic kidney failure (creatinine>2 mg/mL) 3,012 (26.8) 151 (22.4) 2,237 (26.2) 595 (30.9) 29 (29.3) <0.001 12 (0.1) 
Cerebrovascular disease 1,488 (13.2) 84 (12.4) 1,098 (12.8) 286 (14.8) 20 (20.2) 0.019 14 (0.1) 
Atrial fibrillation 5,587 (49.7) 313 (46.4) 4,318 (50.5) 911 (47.3) 45 (45.5) 0.014 11 (0.1) 
Peripheral artery disease 1,060 (9.4) 56 (8.3) 762 (8.9) 233 (12.1) 9 (9.1) <0.001 16 (0.1) 
Heart valve disease 3,020 (26.8) 158 (23.4) 2,329 (27.2) 512 (26.6) 21 (21.2) 0.092 13 (0.1) 
Chronic obstructive pulmonary disease 2,705 (24.1) 145 (21.5) 2,071 (24.2) 470 (24.4) 19 (19.2) 0.262 14 (0.1) 
Dementia 1,454 (12.9) 82 (12.2) 943 (11.0) 400 (20.8) 30 (30.3) <0.001 14 (0.1) 
Active neoplasia 1,581 (14.1) 62 (9.2) 1,211 (14.2) 293 (15.2) 15 (15.2) 0.001 17 (0.2) 
Hepatic cirrhosis 166 (1.5) 4 (0.6) 133 (1.6) 28 (1.5) 1 (1.0) 0.247 27 (0.2) 
Prior episodes of acute heart failure 6,471 (57.9) 327 (49.2) 4,921 (58.0) 1,175 (61.3) 48 (48.5) <0.001 93 (0.8) 
Baseline status        
Barthel Index (points) (mean (SD)) 79 (25) 80 (27) 81 (24) 71 (27) 70 (31) <0.001 1,401 (12.4) 
NYHA class III-IV  2,570 (24.3) 125 (20.1) 1,856 (23.1) 566 (31.2) 23 (25.3) <0.001 702 (6.2) 
Left ventricular ejection fraction (%)(mean (SD)) 52 (15) 51 (15) 52 (15) 50 (16) 47 (15) 0.001 5,053 (44.9) 
Heart failure with reduced ejection fraction (<40%) 1,273 (20.5) 70 (21.9) 915 (19.1) 275 (26.0) 13 (33.3)   
Heart failure with mid-range  ejection fraction (40-49%) 856 (13.8) 41 (12.8) 665 (13.9) 143 (13.5) 7 (17.9)   
Heart failure with preserved ejection fraction (<40%) 4079 (65.7) 209 (65.3) 3,212 (67.0) 639 (60.5) 19 (48.7)   
Chronic treatments at home        
Diuretics (any) 8,164 (74.6) 421 (63.4) 6,285 (75.4) 1,394 (75.6) 64 (65.3) <0.001 322 (2.9) 
ACE inhibitor or ARB 6,218 (56.8) 366 (55.1) 4,751 (57.0) 1,058 (57.4) 43 (43.9) 0.049 323 (2.9) 
Beta-blocker 4,669 (42.7) 299 (45.0) 3,574 (42.9) 757 (41.1) 39 (39.8) 0.267 327 (2.9) 
Mineralocorticoid-receptor antagonist 1,842 (16.8) 91 (13.7) 1,434 (17.2) 305 (16.5) 12 (12.2) 0.073 323 (2.9) 
Digoxin 1,654 (15.1) 86 (13.0) 1,272 (15.3) 282 (15.3) 14 (14.3) 0.441 332 (2.9) 
DECOMPENSATION CHARACTERISTICS        
Vitals at ED during acute episode (mean (SD))        
SBP (mmHg)  141 (27) 141 (27) 142 (26) 139 (32) 125 (30) <0.001 168 (1.5) 
Heart rate (bpm)  88 (24) 89 (25) 88 (23) 91 (25) 88 (24) <0.001 234 (2.1) 










Room air oxygen saturation (%) 92 (7) 93 (6) 93 (6) 90 (8) 91 (7) <0.001 352 (3.1) 
Results of blood tests at ED        
Glucose (mg/dL)(mean (SD)) 149 (85) 152 (73) 145 (79) 164 (110) 167 (85) <0.001 191 (1.7) 
Creatinine (mg/dL)(mean (SD)) 1.35 (0.84) 1.33 (0.94) 1.32 (0.80) 1.48 (0.96) 1.42 (0.84) <0.001 136 (1.7) 
Haemoglobin (g/L)(mean (SD)) 120 (23) 125 (21) 120 (20) 116 (23) 121 (23) <0.001 303 (2.7) 
Potassium (mmol/L)(mean (SD)) 4.42 (0.70) 4.43 (0.71) 4.40 (0.67) 4.53 (0.79) 4.62 (0.76) <0.001 688 (6.1) 
Sodium (mmol/L)(mean (SD)) 138.1 (5.1) 138.1 (4.9) 138.2 (4.9) 137.3 (5.3) 137.3 (5.3) <0.001 235 (2.1) 
Raised troponin (>99th percentile) 3,538 (56.2) 219 (53.2) 2,624 (55.7) 661 (59.1) 34 (64.2) 0.066 4,971 (44.1) 










<0.001 6,259 (55.6) 
Management at ED        
Need for oxygen supplementation 8,010 (71.6) 415 (62.8) 6,109 (71.8) 1,423 (74.1) 63 (64.3) <0.001 71 (0.6) 
Need for intravenous diuretics 9,468 (84.6) 469 (71.0) 7,257 (85.3) 1,675 (87.1) 67 (69.1) <0.001 72 (0.6) 
Need for intravenous/subcutaneous morphine 686 (6.1) 36 (5.4) 363 (4.3) 274 (14.3) 13 (13.3) <0.001 70 (0.6) 
Need for intravenous nitrates 1,512 (13.5) 53 (8.0) 996 (11.7) 453 (23.6) 10 (10.2) <0.001 70 (0.6) 
Need for inotropics/vasopressors 197 (1.8) 6 (0.9) 91 (1.1) 94 (4.9) 6 (6.1) <0.001 74 (0.7) 
Need for non-invasive ventilation 719 (6.4) 24 (3.6) 377 (4.4) 315 (16.4) 3 (3.1) <0.001 71 (0.6) 
Need for mechanical ventilation 320 (5.1) 8 (1.2) 212 (2.5) 95 (4.9) 5 (5.1) <0.001 70 (0.6) 
ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; ED: emergency department; AHF: acute heart failure. 
Bold p values denote statistical significance. 
  










Table 2: Multivariate analysis of outcomes adjusted by differences among groups for the 
whole cohort and stratified by type of episode (de novo/acutely-decompensated), left 
ventricular ejection fraction (below/above 50%), and final disposition after emergency 















1-year all-cause mortality (HR)     
ALL PATIENTS 1 (reference) 1.29 (0.96-1.32) 1.66 (1.40-1.97) 1.67 (1.19-2.35) 
De novo acute heart failure 1 (reference) 1.20 (0.93-1.56) 1.83 (1.38-2.41) 2.21 (1.36-2.41) 
Acutely-decompensated patients 1 (reference) 1.08 (0.88-1.33) 1.54 (1.24-1.91) 1.22 (0.74-1.99) 
LVEF <50% 1 (reference) 1.18 (0.88-1.59) 2.00 (1.50-2.67) 1.60 (0.80-3.19) 
LVEF ≥50% 1 (reference) 1.10 (0.88-1.37) 1.45 (1.16-1.83) 1.72 (1.00-2.95) 
Discharged home 1 (reference) 1.02 (0.70-1.50) 1.98 (1.30-3.00) 2.70 (0.94-7.79) 
Hospitalised 1 (reference) 1.16 (0.97-1.38) 1.56 (1.30-1.89) 1.53 (1.06-2.19) 
Need for hospitalisation (OR)     
ALL PATIENTS 1 (reference) 1.16 (0.97-1.38) 2.02 (1.64-2.50) 2.56 (1.36-4.82) 
De novo acute heart failure 1 (reference) 1.37 (1.08-1.74) 2.65 (1.95-3.61) 2.46 (1.20-5.48) 
Acutely-decompensated patients 1 (reference) 0.94 (0.72-1.24) 1.54 (1.13-2.09) 3.07 (1.06-8.90) 
LVEF <50% 1 (reference) 1.17 (0.85-1.61) 2.13 (1.49-3.05) 4.11 (0.77-21.81) 
LVEF ≥50% 1 (reference) 1.14 (0.90-1.44) 1.96 (1.49-2.57) 2.19 (0.92-5.23) 
Discharged home NA NA NA NA 
Hospitalised NA NA NA NA 
In-hospital all-cause mortality (OR)      
ALL PATIENTS 1 (reference) 1.52 (1.02-2.26) 3.47 (2.31-5.22) 5.70 (3.05-10.65) 
De novo acute heart failure 1 (reference) 1.48 (0.82-2.68) 3.61 (1.96-6.66) 6.15 (2.50-15.10) 
Acutely-decompensated patients 1 (reference) 1.57 (0.92-2.70) 3.44 (1.98-5.98) 5.21 (2.15-12.66) 
LVEF <50% 1 (reference) 1.21 (0.63-2.35) 3.56 (1.80-7.04) 4.42 (1.38-14.12) 
LVEF ≥50% 1 (reference) 1.80 (1.02-3.18) 3.44 (1.90-6.22) 7.12 (2.85-17.82) 
Discharged home NA NA NA NA 
Hospitalised NA NA NA NA 
Prolonged length of stay (>7 days) (OR)     
ALL PATIENTS 1 (reference) 1.27 (1.06-1.51) 1.52 (1.25-1.85) 1.05 (0.66-1.66) 
De novo acute heart failure 1 (reference) 1.40 (1.09-1.81) 1.66 (1.24-2.22) 0.98 (0.50-1.92) 
Acutely-decompensated patients 1 (reference) 1.16 (0.91-1.48) 1.40 (1.07-1.82) 1.18 (0.62-2.23) 
LVEF <50% 1 (reference) 1.23 (0.91-1.65) 1.40 (1.00-1.97) 1.02 (0.47-2.21) 
LVEF ≥50% 1 (reference) 1.29 (1.02-1.62) 1.61 (1.24-2.08) 1.06 (0.55-2.05) 
Discharged home NA NA NA NA 
Hospitalised NA NA NA NA 
7-day post-discharge ED revisit due to AHF (OR)     
ALL PATIENTS 1 (reference) 0.82 (0.60-1.13) 0.98 (0.69-1.40) 0.93 (0.37-2.33) 
De novo acute heart failure 1 (reference) 0.96 (0.58-1.57) 1.03 (0.58-1.84) 1.20 (0.32-4.45) 
Acutely-decompensated patients 1 (reference) 0.74 (0.49-1.12) 0.93 (0.59-1.47) 0.73 (0.20-2.65) 
LVEF <50% 1 (reference) 0.73 (0.43-1.23) 0.80 (0.42-1.51) 0.86 (0.18-4.10) 
LVEF ≥50% 1 (reference) 0.88 (0.58-1.33) 1.11 (0.69-1.79) 1.00 (0.26-3.80) 
Discharged home 1 (reference) 0.83 (0.50-1.37) 1.36 (0.73-2.52) 0.97 (0.10-9.49) 
Hospitalised 1 (reference) 0.84 (0.56-1.26) 1.01 (0.64-1.58) 1.05 (0.38-2.62) 
30-day post-discharge hospitalisation due to AHF (OR)     
ALL PATIENTS 1 (reference) 0.69 (0.54-0.88) 0.73 (0.55-0.97) 0.86 (0.38-1.93) 
De novo acute heart failure 1 (reference) 0.69 (0.46-1.03) 0.86 (0.54-1.39) 0.73 (0.20-2.66) 
Acutely-decompensated patients 1 (reference) 0.68 (0.50-0.93) 0.69 (0.49-0.98) 0.90 (0.32-2.57) 
LVEF <50% 1 (reference) 0.73 (0.46-1.15) 0.81 (0.48-1.38) 0.80 (0.21-2.99) 
LVEF ≥50% 1 (reference) 0.66 (0.48-0.92) 0.69 (0.47-1.01) 0.95 (0.30-3.04) 
Discharged to home 1 (reference) 1.02 (0.60-1.74) 1.23 (0.65-2.33) 2.05 (0.21-20.01) 
Hospitalised 1 (reference) 0.60 (0.45-0.80) 0.63 (0.45-0.86) 0.72 (0.30-1.71) 
LVEF: left ventricular ejection fraction. 
Bold numbersdenote statistical significance










Figure 1: Distribution of clinical phenotypes of acute heart failure, overall and according to the 
department where the patient was hospitalised for the whole cohort (upper panel) and 
stratified (lower panels) by the type of decompensation (de novo/acutely-decompensated) 
and left ventricular ejection fraction (below/above 50%).  
 
P values in bold letters denote statistical significance. 
 In the upper panel, P values for each phenotype refer to comparison of distribution among the main patient destinations after 
emergency care presented in the figure. 
In the middle and lower panel, P values for each final patient destination after emergency department care refer to comparison of 
distribution between patients with de novo (DN) or acutely-decompensated heart failure (ADHF; middle) and patients with left 
ventricular ejection fraction below and above 50% (lower). 










Figure 2: Unadjusted proportional hazard curves for all-cause mortality for the whole cohort (upper 
panel) and stratified (lower panels) according to type of decompensation (de novo/acutely-
decompensated), left ventricular ejection fraction (below/above 50%) and disposition after 
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Figure 3:Percentage of patients developing the secondary endpoints in every clinical phenotype. 
 
  










Figure 4: Unadjusted and adjusted risk ratios for the four clinical phenotypes of acute heart failure 
defined in the 2016 ESC Guidelines6. Adjustment was performed by age, sex, comorbidities 
(hypertension, diabetes mellitus, ischemic heart disease, chronic kidney failure, cerebrovascular disease, 
atrial fibrillation, peripheral artery disease, dementia, active neoplasia, and prior episodes of acute heart 
failure), baseline status (Barthel index, NYHA class, and left ventricular ejection fraction) and chronic 
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Supplemental Table 1: Dictionary of the variables included in the present study. 
DEMOGRAPHICS 
Age Age calculated as the difference in decimal years between the date of inclusion in the study 
and the date of birth. 
Sex Male/Female 
COMORBIDITIES 
Hypertension Indicate if the patient has arterial hypertension because this is shown under previous clinical 
history or the patient is receiving specific treatment.  
Diabetes Mellitus Indicate if the patient has diabetes mellitus because this is shown under previous clinical 
history or the patient is receiving specific treatment.       
Ischemic heart disease Indicate if the patient has any form of ischemic heart disease (SCASEST, SCACEST, unstable 
angina, stable angina, ACI, etc.) because this is shown under previous clinical history or the 
patient is receiving specific treatment.    
Chronic kidney disease Indicate if the patient has chronic renal insufficiency or chronic kidney disease or if analyses 
over the previous year show creatininevalues  >2 mg/dL. 
Cerebrovascular disease Indicate if the patient has had a previous cerebrovascular accident or cerebrovascular disease 
because this is described in the clinical history or shown in CT or MR imaging studies within 
the previous year and reported as cerebrovascular disease. 
Atrial fibrillation Indicate if the previous history describes permanent or chronic atrial fibrillation or an ECG 
performed within the previous year shows atrial fibrillation and this continues to be present.  
Peripheral artery disease Indicate if the patient has peripheral artery disease in either the lower extremities or carotid 
artery, and if the patient is receiving specific treatment, has undergone specific surgery (by-
pass of lower extremities, endarterectomy, etc.) or there is previous history of an ankle 
brachial index <0.90. 
Heart valve disease Indicate if the patient has any type of clinically significant heart valve disease according to an 
ultrasound or hemodynamic study reported in the previous clinical history. 
Chronic obstructive pulmonary disease Indicate if the patient has chronic obstructive pulmonary disease because this is described in 
the clinical history, the patient has undergone spirometry which was not normal or is receiving 
chronic treatment with specific drugs.   
Dementia Indicate if the patient has a previous clinical diagnosis of dementia performed by a doctor. 
Active neoplasia Indicate if the patients has an active neoplasm 
Hepatic cirrhosis Indicate if the patient has a previous clinical diagnosis of hepatic cirrhosis performed by a 
doctor. 
Prior episode of heart failure Indicate if the patient has heart failure, is receiving specific treatment or the clinical history 
reports previous episodes of AHF.  
BASELINE STATUS 
Baseline Barthel index Barthel index value of the patient at least 15 days prior to the date seen in the ED.  
Baseline functional grade for dyspnea 
according to the NYHA scale 
Indicate the functional grade of basal dyspnea (in the 15 days prior to the exacerbation 
episode) of the patient according to the NYHA scale. 
Left ventricular ejection fraction Indicate left ventricular ejection fraction determined by echocardiography during admission of 
current episode or, if not determined, the last one determined during the six previous months 
CHRONIC TREATMENT AT HOME 
Diuretics Receiving chronic treatment with diuretics, either loop-diuretics, thiazide diuretics or 
mineralocorticoid receptor antagonists 
Angiotensin-converter enzyme (ACE) 
inhibitors or angiotensin-II receptor blocker 
Receiving chronic treatment with ACE inhibitors or angiotensin-II receptor blocker 
Beta-blocker Receiving chronic treatment with beta-blocker 
Mineralocorticoid-receptor antagonists Receiving chronic treatment with aldosterone-receptor antagonists 
Digoxin Receiving chronic treatment with Digoxin 
VITAL SIGNS AT EMERGENCY DEPARTMENT ARRIVAL 
Systolic blood pressure Systolic blood pressure (SBP) measured in mmHg of the patient on arrival to the ED. This value 
can be that obtained during triage or the first taken on initiating care.   
Heart rate Central heart rate measured as beats per minute of the patient on arrival to the ED. V This 
value can be that obtained during triage or the first taken on initiating care . 
Arterial oxygen saturation Oxygen saturation expressed as percentage obtained by capillary pulsioxymetry on arrival to 
the ED. This value can be that obtained during triage or the first taken on initiating care.        
BLOOD TESTS AT EMERGENCY DEPARTMENT ARRIVAL 
Glucose In mg/dL 
Creatinine In mg/dL 










Hemoglobin In g/dL 
Potassium In mmol/L 
Sodium In mmol/L 
Raised troponin Indicate if troponin is above the 99th percent provided by the manufacturer 
NT-proBNP In pg/mL 
MANAGEMENT TREATMENT AT EMERGENCY DEPARTMENT 
Oxygen supplementation  Receiving oxygen supplementation, irrespective of the form of administration and 
concentration. 
Intravenous diuretics Receiving intravenous treatment with any kind of diuretic either, in boluses or in continuous 
infusion 
Morphine Receiving treatment with subcutaneous or intravenous morphine in the ED 
Intravenous nitrates Receiving treatment with intravenous nitrates during the first care given in the ED 
Vasoactive drugs Receiving treatment with vasoactive drugs (dopamine, dobutamine, levosimendan, 
noradrenalin, adrenalin) during the first care given in the ED 
Non-invasive ventilation Receiving treatment with non-invasive ventilation during the first care fiven in the ED 
Invasive (mechanical) ventilation Receiving treatment with Invasive (mechanical) ventilation nitrates during the first care given 
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